UNSPSC 51273943: Lidocaine/povidone iodine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273943 Lidocaine/povidone iodine is a Commodity code that, based on recent state and local solicitation activity, appears narrowly matched to the actual purchasing behavior in the source records. The three recent opportunities posted between January and June 2026 reflect procurement of naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products—none of which align directly with the topical antimicrobial agents that the code name suggests. Issuing bodies include a Florida county health department (Seminole County), a state health and human services commission (Texas HHS Commission), and a multistate cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance administering contracts on behalf of Minnesota and Oregon). The mismatch between the code designation and the solicited products indicates that the code may be assigned inconsistently or that state procurement databases tag these broader pharmaceutical acquisitions under this Commodity code despite their different therapeutic classifications.

Geographically, recent activity spans Florida, Texas, and Minnesota/Oregon. Representative opportunities include Seminole County's IFB 60459723LAS for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries (response due July 26, 2023), the Texas HHS Commission's RFI HHS0017013 for direct-to-manufacturer prescription program capabilities (posted April 3, 2026), and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The MMCAP procurement is the most structured formal solicitation, requiring cGMP and DSCSA certification, relationships with at least two of three authorized wholesalers, and pricing flexibility through multiple formats; vendors must carry $5 million commercial general liability coverage and $2 million network security and privacy liability. Given the disconnect between the stated code scope and the products actually being procured, this code shows little directly relevant recent activity for firms focused on topical antimicrobials.